EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing

Zinger Key Points

Single dose of Vivani’s NPM-139 semaglutide implant led to nearly 20% weight loss in rats, suggesting once- or twice-yearly dosing.
NPM-139 showed steady semaglutide release with potential for once-yearly administration, supported by over a year of in vitro stability data
Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.

Vivani Medical, Inc. VANI, on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight individuals.

Semaglutide is the active ingredient in Novo Nordisk A/S’ NVO Ozempic and Wegovy, which are available for diabetes and weight loss.

In an ongoing study in healthy rats, a single administration of the semaglutide implant NPM-139 resulted in body weights nearly 20% lower than a sham implant control group throughout a 91-day treatment period.

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing.

Also Read: EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value

Like NPM-119 and NPM-115, NPM-139 has demonstrated smooth, non-fluctuating in vivo release. The study demonstrated continuous and steady semaglutide exposure throughout the study period.

NPM-139 has previously demonstrated therapeutic semaglutide exposure levels in pharmacokinetic data over six months in healthy rats.

In-vitro chemical and physical stability measurements for durations exceeding one year indicate the potential for once-yearly administration of NPM-139.

The ongoing NPM-115 clinical study, LIBERATE-1, remains on track to produce top-line data by mid-2025.

Earlier this month, Vivani Medical announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 trial in Australia.

Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals.

Last year, Vivani Medical released preclinical data on weight loss effects for NPM-115.

In a study in high-fat diet-induced obese mice, NPM-115 generated weight loss of approximately 20% compared to a sham implant control after a 28-day treatment duration.

Price Action: VANI stock closed at $1.10 on Tuesday.

Read Next: